171 related articles for article (PubMed ID: 21729658)
41. Fulvestrant and the sequential endocrine cascade for advanced breast cancer.
Johnston S
Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S15-8. PubMed ID: 15094760
[TBL] [Abstract][Full Text] [Related]
42. Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience.
Ishida N; Araki K; Sakai T; Kobayashi K; Kobayashi T; Fukada I; Hosoda M; Yamamoto M; Ichinokawa K; Takahashi S; Iwase T; Ito Y; Yamashita H
Breast Cancer; 2016 Jul; 23(4):617-23. PubMed ID: 25896598
[TBL] [Abstract][Full Text] [Related]
43. Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
Safra T; Greenberg J; Ron IG; Ben-Yosef R; Inbar M; Sarid D; Yaal-Hahoshen N
Isr Med Assoc J; 2008 May; 10(5):339-43. PubMed ID: 18605354
[TBL] [Abstract][Full Text] [Related]
44. Clinical development of fulvestrant ("Faslodex").
Howell A; Abram P
Cancer Treat Rev; 2005; 31 Suppl 2():S3-9. PubMed ID: 16198055
[TBL] [Abstract][Full Text] [Related]
45. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).
Pritchard KI; Rolski J; Papai Z; Mauriac L; Cardoso F; Chang J; Panasci L; Ianuli C; Kahan Z; Fukase K; Lindemann JP; Macpherson MP; Neven P
Breast Cancer Res Treat; 2010 Sep; 123(2):453-61. PubMed ID: 20632084
[TBL] [Abstract][Full Text] [Related]
46. ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data.
Robertson JF
Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):11-4. PubMed ID: 11900210
[TBL] [Abstract][Full Text] [Related]
47. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.
Robertson JF; Howell A; Gorbunova VA; Watanabe T; Pienkowski T; Lichinitser MR
Breast Cancer Res Treat; 2005 Jul; 92(2):169-74. PubMed ID: 15986127
[TBL] [Abstract][Full Text] [Related]
48. Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
Tobias JS
Int J Biochem Cell Biol; 2004 Nov; 36(11):2112-9. PubMed ID: 15313457
[TBL] [Abstract][Full Text] [Related]
49. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.
Osborne CK; Wakeling A; Nicholson RI
Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S2-6. PubMed ID: 15094757
[TBL] [Abstract][Full Text] [Related]
50. Endocrine therapy for the treatment of postmenopausal women with breast cancer.
Harichand-Herdt S; Zelnak A; O'Regan R
Expert Rev Anticancer Ther; 2009 Feb; 9(2):187-98. PubMed ID: 19192957
[TBL] [Abstract][Full Text] [Related]
51. Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models.
Cope S; Ouwens MJ; Jansen JP; Schmid P
Value Health; 2013; 16(2):403-17. PubMed ID: 23538193
[TBL] [Abstract][Full Text] [Related]
52. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.
Bartsch R; Bago-Horvath Z; Berghoff A; DeVries C; Pluschnig U; Dubsky P; Rudas M; Mader RM; Rottenfusser A; Fitzal F; Gnant M; Zielinski CC; Steger GG
Eur J Cancer; 2012 Sep; 48(13):1932-8. PubMed ID: 22459763
[TBL] [Abstract][Full Text] [Related]
53. Can estrogen receptor overexpression in normal tissues due to previous estrogen deprivation explain the fulvestrant efficacy in breast cancer therapy?
Kurbel S
Med Hypotheses; 2012 Dec; 79(6):869-71. PubMed ID: 23062772
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of fulvestrant in clinical practice: use of an electronic data registry.
Lower EE; Esparaz BT; Garnett SA; Wade JL
Clin Breast Cancer; 2007 Apr; 7(7):565-9. PubMed ID: 17509166
[TBL] [Abstract][Full Text] [Related]
55. Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy.
Deeks ED
Drugs; 2018 Jan; 78(1):131-137. PubMed ID: 29270913
[TBL] [Abstract][Full Text] [Related]
56. Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme.
Steger GG; Gips M; Simon SD; Lluch A; Vinholes J; Kaufman B; Wardley A; Mauriac L
Cancer Treat Rev; 2005; 31 Suppl 2():S10-6. PubMed ID: 16198057
[TBL] [Abstract][Full Text] [Related]
57. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance.
Dowsett M; Nicholson RI; Pietras RJ
Breast Cancer Res Treat; 2005; 93 Suppl 1():S11-8. PubMed ID: 16247595
[TBL] [Abstract][Full Text] [Related]
58. Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer.
Robertson JF; Semiglazov V; Nemsadze G; Dzagnidze G; Janjalia M; Nicholson RI; Gee JM; Armstrong J;
Eur J Cancer; 2007 Jan; 43(1):64-70. PubMed ID: 17064888
[TBL] [Abstract][Full Text] [Related]
59. Fulvestrant - a novel endocrine therapy for breast cancer.
Johnston SJ; Cheung KL
Curr Med Chem; 2010; 17(10):902-14. PubMed ID: 20156170
[TBL] [Abstract][Full Text] [Related]
60. Fulvestrant.
Cheung KL; Robertson JF
Expert Opin Investig Drugs; 2002 Feb; 11(2):303-8. PubMed ID: 11829719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]